Multiplexing detection of IgG against Plasmodium falciparum pregnancy-specific antigens

PLoS One. 2017 Jul 17;12(7):e0181150. doi: 10.1371/journal.pone.0181150. eCollection 2017.

Abstract

Background: Pregnant women exposed to Plasmodium falciparum generate antibodies against VAR2CSA, the parasite protein that mediates adhesion of infected erythrocytes to the placenta. There is a need of high-throughput tools to determine the fine specificity of these antibodies that can be used to identify immune correlates of protection and exposure. Here we aimed at developing a multiplex-immunoassay to detect antibodies against VAR2CSA antigens.

Methods and findings: We constructed two multiplex-bead arrays, one composed of 3 VAR2CSA recombinant-domains (DBL3X, DBL5Ɛ and DBL6Ɛ) and another composed of 46 new peptides covering VAR2CSA conserved and semi-conserved regions. IgG reactivity was similar in multiplexed and singleplexed determinations (Pearson correlation, protein array: R2 = 0.99 and peptide array: R2 = 0.87). IgG recognition of 25 out of 46 peptides and all recombinant-domains was higher in pregnant Mozambican women (n = 106) than in Mozambican men (n = 102) and Spanish individuals (n = 101; p<0.05). Agreement of IgG levels detected in cryopreserved plasma and in elutions from dried blood spots was good after exclusion of inappropriate filter papers. Under heterogeneous levels of exposure to malaria, similar seropositivity cutoffs were obtained using finite mixture models applied to antibodies measured on pregnant Mozambican women and average of antibodies measured on pregnant Spanish women never exposed to malaria. The application of the multiplex-bead array developed here, allowed the assessment of higher IgG levels and seroprevalences against VAR2CSA-derived antigens in women pregnant during 2003-2005 than during 2010-2012, in accordance with the levels of malaria transmission reported for these years in Mozambique.

Conclusions: The multiplex bead-based immunoassay to detect antibodies against selected 25 VAR2CSA new-peptides and recombinant-domains was successfully implemented. Analysis of field samples showed that responses were specific among pregnant women and dependent on the level of exposure to malaria. This platform provides a high-throughput approach to investigating correlates of protection and identifying serological markers of exposure for malaria in pregnancy.

MeSH terms

  • Adult
  • Antibodies, Protozoan / blood*
  • Antibodies, Protozoan / immunology
  • Antigens, Protozoan / genetics
  • Antigens, Protozoan / immunology*
  • Antigens, Protozoan / metabolism
  • Dried Blood Spot Testing
  • Erythrocytes / parasitology
  • Female
  • Humans
  • Immunoassay*
  • Immunoglobulin G / blood*
  • Immunoglobulin G / immunology
  • Malaria, Falciparum / diagnosis
  • Malaria, Falciparum / epidemiology
  • Malaria, Falciparum / parasitology
  • Mozambique / epidemiology
  • Plasmodium falciparum / isolation & purification
  • Plasmodium falciparum / metabolism*
  • Pregnancy
  • Protein Array Analysis*
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / immunology
  • Recombinant Proteins / isolation & purification
  • Young Adult

Substances

  • Antibodies, Protozoan
  • Antigens, Protozoan
  • Immunoglobulin G
  • Recombinant Proteins
  • VAR2CSA protein, Plasmodium falciparum

Grants and funding

Supported by the Malaria Eradication Scientific Alliance (MESA), the European and Developing Countries Clinical Trials Partnership (EDCTP), the Malaria in Pregnancy (MiP) Consortium, and grants from Banco de Bilbao, Vizcaya, Argentaria Foundation (BBVA 02-0), Instituto de Salud Carlos III (grants PS09/01113 and PI13/01478 cofounded by the Fondo Europeo de Desarrollo Regional [FEDER], and CES10/021-I3SNS to AM), AGAUR/Generalitat de Catalunya (2014 SGR 263) and The Fundação para a Ciência e Tecnologia (SFRH/BD/51696/2011 to AMF). ISGlobal received support from the CERCA programme/Generalitat de Catalunya. The Centro de Investigação em Saúde da Manhiça (CISM) receives core support from the Spanish Agency for International Cooperation and Development. The MiP Consortium and MESA are funded through a grant from the Bill and Melinda Gates Foundation to the Liverpool School of Tropical Medicine and the Barcelona Institute of Global Health, respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.